Arbor Rapha Capital Bioholdings Corp. I
ARCKW
NASDAQ Global Market0.10
USD
- -
- -
Arbor Rapha Capital Bioholdings Corp. I
ARCKW
(NASDAQ Global Market)
Recent
price
0.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Arbor Rapha Capital Bioholdings Corp. I operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting opportunities in the biopharmaceutical sector with disruptive technologies aimed at transforming healthcare. The company offers no current products or services beyond its SPAC structure, which includes Class A common stock traded under the ticker ARCK and redeemable warrants under ARCKW, each entitling holders to purchase one share of Class A common stock at $11.50 per share; it maintains a trust account holding proceeds from its initial public offering for potential deployment in a business combination. Incorporated in 2021 and headquartered in Uniondale, New York, the company conducts operations principally in the United States and globally within the biopharmaceutical investment space, with a management team led by CEO Ivan Kaufman and affiliations to Arbor Rapha Capital LLC and Rapha Capital Management, LLC. In recent developments, Arbor Rapha Capital Bioholdings Corp. I completed its initial public offering in November 2021, raising $172.5 million through 17.25 million units at $10.00 each, including the full exercise of underwriters' over-allotment option by Cantor Fitzgerald & Co., with units separating into Class A shares and warrants on December 20, 2021. The company failed to identify or complete a business combination within its extended deadline, leading stockholders to approve an amendment on March 3, 2023, accelerating liquidation to March 7, 2023, after which it formally notified Nasdaq of its intent to dissolve, requested delisting via Form 25, and redeemed outstanding Class A shares at approximately their pro-rata trust value, with minimal redemptions of about 6.9% of shares; trading was halted by Nasdaq in January 2023 pending news related to these events. As of late 2025, the company remains in a liquidated status with no active operations, target acquisitions, or ongoing offerings, and its warrants (ARCKW) trade on a residual basis reflecting post-liquidation market dynamics.